Skip to main content

gastrointestinal stromal tumors

Conference Insider
06/15/2021
Results following the phase Ib portion in the evaluation of imatinib in combination with selinexor displays well tolerability in patients with imatinib (IM)-resistant, advanced GIST, presented at the 2021 ASCO Annual Meeting.
Results following the phase Ib portion in the evaluation of imatinib in combination with selinexor displays well tolerability in patients with imatinib (IM)-resistant, advanced GIST, presented at the 2021 ASCO Annual Meeting.
Results following the phase Ib...
06/15/2021
Oncology
Research in Review
02/22/2017
JCP Editors
Imatinib mesylate front-line treatment of advanced or metastatic gastrointestinal stromal tumors (GISTs) leads to significant long-term survival in patients with a specific genetic mutation, according to study...
Imatinib mesylate front-line treatment of advanced or metastatic gastrointestinal stromal tumors (GISTs) leads to significant long-term survival in patients with a specific genetic mutation, according to study...
...
02/22/2017
Journal of Clinical Pathways
Research in Review
01/10/2017
JCP Editors
The best potential strategy involving tyrosine kinase inhibitors (TKIs) for the treatment of gastrointestinal stromal tumors (GISTs) has been identified, according to new research published in Clinical Drug...
The best potential strategy involving tyrosine kinase inhibitors (TKIs) for the treatment of gastrointestinal stromal tumors (GISTs) has been identified, according to new research published in Clinical Drug...
The...
01/10/2017
Journal of Clinical Pathways